“We aimed to investigate the relationship between iron deficiency and pruritus in pregnant women without primary skin disease,” Dr Kerem Balan (Hacettepe University, Ankara, Turkey) explained [1]. The study included pregnant women with generalised pruritus (N=68) but no prior history of itch and a comparison group of women with other skin problems (N=31) between 2016 and 2024.
The groups were compared for demographics and laboratory results. Pregnant women with pruritus differed significantly from those without in age (28.9 vs 31.6 years; P=0.026), ferritin levels (24.0 vs 39.3 ng/mL; P<0.01), vitamin B12 (161.4 vs 250.2 pg/mL, P<0.01), haemoglobin (11.5 vs 12.3 g/dL, P=0.03), gestational week (25.23 vs 21.21; P=0.035) and total iron-binding capacity (TIBC) (436.4 vs 378.6 mcg/dL; P=0.017).
After determining optimal cut-off values for vitamin B12 and ferritin through univariate analysis, the researchers performed a multivariate regression to identify factors significantly associated with pruritus in pregnant women. Age, gestational week, and vitamin B12 <197.5 pg/mL were not significantly associated, but ferritin < 20 ng/mL was strongly linked to pruritus, with an odds ratio of 21.9 (95% CI 5.9-80.03; P<0.001). These findings suggest a potential aetiologic role of iron deficiency in pruritus during pregnancy.
“Iron deficiency is a major risk factor for pruritus in pregnancy. Early detection and management of iron deficiency may relieve symptoms and improve maternal well-being,” Dr Balan concluded. He also noted the need for further research, as the presented study was retrospective.
- Balan K, et al. Pruritus in pregnancy: is there a link to iron deficiency? EPS04.05, EADV Congress 2025, 17–20 September, Paris, France.
Medical writing support was provided by Dr Susanne Kammerer and Karin Drooff
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Clinically meaningful and durable response of mosunetuzumab in MZL Next Article
CHE in adolescents: Delgocitinib cream superior to vehicle »
« Clinically meaningful and durable response of mosunetuzumab in MZL Next Article
CHE in adolescents: Delgocitinib cream superior to vehicle »
Table of Contents: EADV 2025
Featured articles
Cohort study links GLP-1RAs therapy to elevated risk of nonscarring hair loss
Earlier skin cancer diagnosis and high patient satisfaction with patient-led teledermoscopy
More than skin deep: Atopic eczema linked to higher suicide risk across all ages
Online First
Cohort study links GLP-1RAs therapy to elevated risk of nonscarring hair loss
Psoriasis: Tapering of IL-23 or IL-17 inhibition is non-inferior to usual care
Pooled analysis confirms a consistent safety profile of delgocitinib cream in CHE
Extended-release oral minoxidil: a rising star in the treatment of androgenic alopecia?
Early treatment response predicts long-term stability with tralokinumab in AD
Earlier skin cancer diagnosis and high patient satisfaction with patient-led teledermoscopy
Targeting the OX40 pathway: a novel therapeutic approach in AD
CSU: Rapid symptom relief with remibrutinib
Alopecia areata: ritlecitinib demonstrates sustained efficacy for up to 3 years
Topical ruxolitinib: a new hope for patients with prurigo nodularis?
More than skin deep: Atopic eczema linked to higher suicide risk across all ages
Beyond glycaemic control: GLP-1RAs reduce cardiovascular and psychiatric risk in psoriasis
HS: Promising clinical benefits with izokibep
CHE in adolescents: Delgocitinib cream superior to vehicle
Low ferritin levels in pregnancy are associated with a higher probability of generalised pruritus
Related Articles
December 20, 2018
New agents and combination therapy
August 31, 2023
Can lebrikizumab maintain response rates in atopic dermatitis?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
